SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on compliance, privacy, and real-world utility, particularly its advancements in stablecoins and PayFi. Recent partnerships, including integration with bitcoin.com wallets for age-verified stablecoin payments, are generating excitement. Many believe $CCD is positioned to be a key infrastructure player in the evolving regulatory landscape of blockchain and digital finance.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community speculates on potential breakouts and considers it an undervalued cryptocurrency. Some view LTC as a strong buy under $100, citing its long-term adoption and recent privacy upgrades. Discussions also revolve around its relationship with Bitcoin's price movements and whether it signals a broader altcoin season.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

$SWEAT is trending as the community anticipates its potential, with many expressing long-term bullish sentiment. Discussions revolve around staking, accumulating coins through the Sweatcoin app by walking, and hopes for a future bull run. Some users are highlighting its unique incentive for healthy activity, while others await broader availability and speculate on future price movements.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

PGY is trending amid community discussion around its valuation and potential compared to fintech peers like UPST and AFRM. Some believe PGY is undervalued, citing its growth potential and AI-driven model, while others express concern over market volatility and potential impact from economic factors. Upcoming earnings and potential catalysts like government deregulation are also focal points.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the community discusses its recent partnership with Nvidia for autonomous driving technology and a collaboration with Uber, despite mixed sentiment regarding the company's financial health and leadership. Investors are weighing the potential of these deals against concerns about profitability and dilution. Bullish traders are hoping for a short squeeze.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending amid discussions about its potential for growth and recent partnerships, with community members pointing to a Nasdaq-listed company's planned investment in AVAX tokens as a catalyst. The community is actively debating entry points and speculating on short-term price movements. Some traders anticipate a broader altcoin season could further boost AVAX.

GigaCloud Technology, Inc. specializes in global end-to-end business-to-business (B2B) electronic commerce (e-commerce) for large parcel merchandise. Its B2B ecommerce platform, the “GigaCloud Marketplace” integrates everything from discovery, payments and logistics tools into one easy-to-use platform. The firm offers a comprehensive solution that transports products from the manufacturers warehouse to the end customers doorstep, all in one place. The company was founded by Lei Wu on August 29, 2006 and is headquartered in El Monte, CA.

GigaCloud Technology Inc - Ordinary Shares - Class A

GigaCloud Technology Inc

GigaCloud Technology ($GCT) is trending as investors discuss its low P/E ratio and growth potential despite mixed sentiment around tariffs and potential insider selling; the community awaits the upcoming earnings report with anticipation of a strong showing that could catalyze a price surge. A recent settlement regarding claims of misleading investors is also circulating, though some believe GCT's unique logistics model and expansion into Europe position it for long-term success.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot ($DOT) is trending amidst mixed sentiment, with discussions around potential ETF approvals and ecosystem developments like Aventus Network integration. While some community members express frustration with price action and tokenomics, others highlight staking opportunities and the project's long-term potential in Web3. Speculation around a hard cap on the DOT supply is also fueling debate.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE crypto is trending as the community buzzes about a new listing and upcoming portal launch with updates. Token buybacks are underway, fueling speculation of significant moves, while some compare its potential to previous runners and highlight its low market cap on Coinbase. Community members are closely watching for a breakout, citing increased volume and bullish chart patterns.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a significant sell-off following earnings, despite the company beating expectations; the community is actively debating whether this drop is an overreaction or a sign of deeper issues. Community members are also discussing the impact of AI on the company's future, as well as a recent analyst downgrade. Despite the negative sentiment, some investors view the dip as a buying opportunity, citing the company's strong fundamentals and growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk...

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."read more...

Pfizer Sweetens Offer For Metsera To $86.25/shr Amid Escalating Bidding War With Novo Nordisk

(RTTNews) - Metsera Inc. (MTSR) announced that it has entered into an amended merger agreement with Pfizer, under which Pfizer will acquire Metsera for up to $86.25 per share. The deal includes...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's...

Metsera (NASDAQ:MTSR) Trading Up 10.6% - Still a Buy?

Metsera (NASDAQ:MTSR) Trading 10.6% Higher - Here's What Happened...

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

Investors Purchase High Volume of Put Options on Metsera (NASDAQ:MTSR)

Metsera Inc. (NASDAQ:MTSR - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock traders purchased 2,401 put options on the company. This represents an increase of...

Tesla Investors Approve Musk Pay Package, Comcast's Sky in Talks to Buy ITV  The Opening Trade 11/7

Tesla shareholders approved a potential $1 trillion compensation package for Chief Executive Officer Elon Musk, the largest payout ever awarded to a corporate leader. Musk would have to meet certain...

<ul class="summary-bullets"><li>The details of the new bid could not be immediately ascertained, FT said.</li><li>Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</li><li>Pfizer reportedly matched Novo’s last offer late on Wednesday, prompting Novo’s new bid. &nbsp;</li></ul>Danish drugmaker Novo Nordisk has reportedly sweetened its bid further for obesity drug maker Metsera amid a rising bidding war with Pfizer.The Financial Times<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1"> reported</a> on Thursday, citing people familiar with the matter, that Novo raised its bid after Pfizer matched its last offer, valuing the company at up to $10 billion, late on Wednesday.The details of the new bid could not be immediately ascertained, FT said. Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;<h2 class="st-heading-2">Start Of The Bidding War</h2>Novo Nordisk first announced last week that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera determined that Novo’s bid was superior and gave Pfizer a certain number of days to negotiate the terms of their agreement. &nbsp;On Monday, Metsera said that it has received revised bids from both Pfizer and Novo, valuing the company at up to $8.1 billion and $10 billion, respectively. Pfizer reportedly matched Novo’s offer late on Wednesday, prompting Novo’s new bid.Pfizer had requested a temporary restraining order from the Delaware Chancery Court last week to prevent Metsera from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. However, the court denied the request on Wednesday. Pfizer, however, said that it intends to pursue further litigation and expressed confidence in the merit of claims that Metsera has acted in breach of its contractual obligations. Metsera, on its side, dismissed Pfizer’s arguments as “nonsense.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> soared 14% at the time of writing. On Stocktwits, retail sentiment around MTSR stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.MTSR stock has more than tripled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnson-newly-acquired-antipsychotic-drug-approved-by-fda-for-major-depressive-disorder/cL2tuwZRERN">Johnson &amp; Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 

Equity

<ul class="summary-bullets"><li>Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.</li><li>The court decision follows Metsera’s board reaffirming Novo’s revised $86.20-per-share offer as superior to Pfizer’s $8.1 billion counterproposal.</li><li>Pfizer vowed to continue its legal and antitrust challenges in Delaware federal court.</li></ul>Novo Nordisk’s U.S.-listed shares rose Wednesday, ending an 11-session losing streak, after a Delaware judge rejected Pfizer's request to block the Danish company’s $10 billion acquisition of obesity-drug startup Metsera Inc.Delaware Chancery Judge Morgan Zurn said Pfizer’s objections didn’t warrant delaying the transaction and found no evidence Metsera’s board acted in bad faith when it labeled Novo’s offer “superior.” The ruling allows Novo to proceed with the deal, which topped Pfizer’s earlier $4.9 billion agreement announced in September, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-05/pfizer-loses-legal-bid-to-temporarily-block-novo-s-metsera-offer">report</a>.<h2 class="st-heading-2">Revised Offers Raise The Stakes</h2>On Tuesday, Metsera said it received a revised offer from Novo valuing the company at up to $86.20 per share, or about $10 billion. The new proposal includes $62.20 per share in cash, up from $56.50 in the original bid, plus contingent value rights worth up to $24.00 per share if certain milestones are achieved.Pfizer also revised its terms, increasing upfront consideration to $60 per share and trimming the contingent payout to $10 per share, valuing its bid at roughly $8.1 billion. Despite the adjustment, Metsera’s board reaffirmed Novo’s offer as superior and gave Pfizer two business days to counter before terminating its merger agreement.<h2 class="st-heading-2">Pfizer Vows To Keep Fighting</h2>Pfizer said the ruling “fails to address the legal issues raised” and vowed to continue litigation in Delaware federal court, calling Novo’s bid “an unprecedented and illegal scheme to circumvent antitrust scrutiny.” The company alleges Novo’s move is designed to protect its dominance in the GLP-1 obesity-drug space by neutralizing a future competitor.Novo countered that the court’s ruling validates its approach and serves shareholders’ best interests. Its offer, which includes both upfront and milestone-based payments, aims to bring Metsera’s experimental weight-loss portfolio, which is a potential rival to Ozempic and Wegovy, under its umbrella.<h2 class="st-heading-2">FTC Flags Premerger Concerns</h2>The U.S. Federal Trade Commission warned that Novo’s offer could breach the Hart-Scott-Rodino Act if completed without premerger review. In a Nov. 4 letter, the FTC said the structure of Novo’s bid, which grants substantial upfront payments before regulatory approval, could reduce Metsera’s independence and incentive to pursue its drug pipeline.<h2 class="st-heading-2">Stocktwits Bulls Cheer, Bears Question The Deal</h2>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid a 159% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:964/138;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_016bd02a5d.webp" alt="nvo ss.jpg" width="964" height="138"><figcaption>NVO sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure>One user suggested that better days could be close, urging others to “hold strong.”<stembedurl>https://stocktwits.com/RunGoodStreakAlive/message/635121830</stembedurl>Another user, however, questioned whether Novo’s management understood investor sentiment, noting that Pfizer’s stock tends to rise each time it appears closer to reclaiming the Metsera deal, suggesting that shareholders aren’t convinced by Novo’s acquisition push.<stembedurl>https://stocktwits.com/GreenHawkz/message/635102183</stembedurl><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 43% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.72	--	--	N/A
Q2 '25	-$0.66	-$0.66	-0.29%	MISSED
Q1 '25	-$0.94	-$1.03	-8.99%	MISSED
Q4 '24	-$0.61	-$3.52	-477.05%	MISSED

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest MTSR News

MTSRMetsera Inc